Relapsing and progressive MS: the sex-specific perspective.
age of onset
multiple sclerosis
progressive MS
relapsing MS
sex ratio
Journal
Therapeutic advances in neurological disorders
ISSN: 1756-2856
Titre abrégé: Ther Adv Neurol Disord
Pays: England
ID NLM: 101480242
Informations de publication
Date de publication:
2020
2020
Historique:
received:
11
04
2020
accepted:
08
08
2020
entrez:
8
10
2020
pubmed:
9
10
2020
medline:
9
10
2020
Statut:
epublish
Résumé
Multiple sclerosis (MS) is an inflammatory and neurodegenerative disease whose aetiology is not fully understood. The female sex is clearly predominant, with a sex ratio between 2 and 3. In primary progressive MS the sex ratio almost balances out. Since the age at onset is higher for patients with progressive onset (POMS) than for relapsing onset (ROMS), it can be hypothesized that the age at onset is a decisive factor for the sex ratio. To address this aspect, we compare clinical and demographic data between females and males for the different disease courses within the population of the German MS Register by the German MS Society. Only patients with complete details in mandatory data items and a follow-up visit since 01. Jan 2018 were included. A total of 18,728 patients were included in our analyses, revealing a female-to-male ratio of 2.6 (2.7 for patients with ROMS and 1.3 for POMS). The age at diagnosis is higher in patients with POMS (43.3 and 42.3 years for females and males Our analysis shows that clinical and demographic data differ more between disease courses than between men and women. For pain, depression and cognitive impairment the female sex is the decisive factor. Whether these factors are responsible for the earlier retirement of females with ROMS is not clear. Appropriate measures for optimization of symptomatic treatment as well as to promote employment should be taken.
Sections du résumé
BACKGROUND
BACKGROUND
Multiple sclerosis (MS) is an inflammatory and neurodegenerative disease whose aetiology is not fully understood. The female sex is clearly predominant, with a sex ratio between 2 and 3. In primary progressive MS the sex ratio almost balances out. Since the age at onset is higher for patients with progressive onset (POMS) than for relapsing onset (ROMS), it can be hypothesized that the age at onset is a decisive factor for the sex ratio.
METHODS
METHODS
To address this aspect, we compare clinical and demographic data between females and males for the different disease courses within the population of the German MS Register by the German MS Society. Only patients with complete details in mandatory data items and a follow-up visit since 01. Jan 2018 were included.
RESULTS
RESULTS
A total of 18,728 patients were included in our analyses, revealing a female-to-male ratio of 2.6 (2.7 for patients with ROMS and 1.3 for POMS). The age at diagnosis is higher in patients with POMS (43.3 and 42.3 years for females and males
CONCLUSION
CONCLUSIONS
Our analysis shows that clinical and demographic data differ more between disease courses than between men and women. For pain, depression and cognitive impairment the female sex is the decisive factor. Whether these factors are responsible for the earlier retirement of females with ROMS is not clear. Appropriate measures for optimization of symptomatic treatment as well as to promote employment should be taken.
Identifiants
pubmed: 33029201
doi: 10.1177/1756286420956495
pii: 10.1177_1756286420956495
pmc: PMC7521047
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1756286420956495Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: PSR received research grants from Biogen, Merck, Roche; consultancy or speaker fees from Almirall, Biogen, Celgene, Merck, Roche, Novartis, Sanofi Genzyme, Sandoz. None of them resulted in a conflict of interest regarding the submitted work. DE declares no conflict of interest. KH has received speakingfees, travel support, and research honoraria from Biogen,Teva, Sanofi-Genzyme, Novartis, Bayer Healthcare, MerckSerono, and Roche. None resulted in a conflict of interest. JH declares no conflict of interest to the submitted work. DP received research grants from Sandoz, Schering, Biogen; speaker fees from Almirall, Bayer, Biogen, Merck, Novartis, Roche, Sanofi Genzyme and Teva. None of them resulted in a conflict of interest regarding the submitted manuscript. Alexander Stahmann reports institutional Grants for the enhancement of the German MS-Register by Biogen, Celgene, Merck and Novartis, all outside this study. UKZ received speaker fees from Alexion, Almirall, Bayer, Biogen, Merck, Novartis, Roche, Sanofi Genzyme and Teva. None of them resulted in a conflict of interest regarding the submitted manuscript.
Références
Neural Regen Res. 2017 Apr;12(4):509-517
pubmed: 28553319
Arthritis Rheum. 1978 May;21(4):480-4
pubmed: 656163
Lancet. 2018 Apr 21;391(10130):1622-1636
pubmed: 29576504
J Neurol Neurosurg Psychiatry. 2017 Feb;88(2):137-145
pubmed: 27671902
Mult Scler. 2014 Apr;20(4):513-4
pubmed: 23921135
Neurology. 2014 Jul 15;83(3):278-86
pubmed: 24871874
Immunology. 2019 Jan;156(1):9-22
pubmed: 30222193
Ann Neurol. 2017 Nov;82(5):795-812
pubmed: 29059494
Lancet Neurol. 2015 Feb;14(2):183-93
pubmed: 25772897
Clin Immunol. 2013 Nov;149(2):201-10
pubmed: 23608496
Lancet Neurol. 2007 Oct;6(10):903-12
pubmed: 17884680
Autoimmun Rev. 2012 Jan;11(3):167-73
pubmed: 21619943
Biol Sex Differ. 2016 Jan 12;7:3
pubmed: 26759713
Nat Rev Rheumatol. 2016 Nov 22;12(12):716-730
pubmed: 27872476
Curr Top Behav Neurosci. 2015;26:57-86
pubmed: 25690592
Mult Scler. 2019 Oct;25(12):1641-1652
pubmed: 30230952
J Neurol. 2020 Jul;267(7):2042-2053
pubmed: 32219555
Neurology. 2018 May 29;90(22):e1954-e1963
pubmed: 29720546
CNS Neurosci Ther. 2019 Jan;25(1):78-85
pubmed: 29858532
Best Pract Res Clin Rheumatol. 2013 Jun;27(3):435-47
pubmed: 24238698
Nervenarzt. 2005 Aug;76(8):967-75
pubmed: 15806419
Mult Scler. 2013 Jan;19(1):3-4
pubmed: 23303878
Nat Rev Neurol. 2012 Mar 27;8(5):255-63
pubmed: 22450508
Front Neurol. 2017 Sep 05;8:461
pubmed: 28928713
Front Neuroendocrinol. 2019 Oct;55:100787
pubmed: 31513774
Mult Scler. 2013 Jan;19(1):46-52
pubmed: 22711712
Front Immunol. 2019 Jan 10;9:3116
pubmed: 30687321
Mult Scler. 2010 May;16(5):520-5
pubmed: 20215479
Neuroendocrinology. 2020 Mar 11;:
pubmed: 32155633
Ann Gen Psychiatry. 2015 Sep 22;14:29
pubmed: 26401158
Front Immunol. 2020 Feb 07;11:137
pubmed: 32117284
PLoS One. 2016 Sep 15;11(9):e0160261
pubmed: 27632167
Eur Neurol. 2018;80(1-2):93-99
pubmed: 30343306
Ther Adv Neurol Disord. 2013 Jul;6(4):237-48
pubmed: 23858327
Neurology. 2008 Jul 8;71(2):129-35
pubmed: 18606967
Front Immunol. 2018 Jun 04;9:1269
pubmed: 29915601
N Engl J Med. 2018 Jan 11;378(2):169-180
pubmed: 29320652
Lancet Neurol. 2010 May;9(5):520-32
pubmed: 20398859
Lancet Neurol. 2006 Nov;5(11):932-6
pubmed: 17052660
Neuroscientist. 2001 Jun;7(3):258-70
pubmed: 11499404
N Engl J Med. 1998 Jul 30;339(5):285-91
pubmed: 9682040
Front Immunol. 2018 Mar 28;9:611
pubmed: 29643853
Curr Opin Neurol. 2019 Jun;32(3):378-384
pubmed: 30865009
Ann Neurol. 2015 Nov;78(5):710-21
pubmed: 26239536